Topical toxin gels progress well in trials

Two American companies have two skin products in development that contain botulininum toxin A. These two products, currently known as RT1001 and Cosmetox,  are being trialled at the moment and early results sound to be encouraging. The cream has been used in the crow’s feet area, and four weeks after treatment 85% of subjects in one trial reported at least 75% improvement.

Whilst it sounds to be some time away from being marketed in the UK, it could potentially provide an alternative type of treatment for needle-phobic people, and also may help prolong the action of injected botox. There doesn’t appear to have been any trials comparing its results with those of injected botox yet.

(Extracted from Body Language Issue 35 – September/October 2009)